Acta Scientific Ophthalmology (ISSN: 2582-3191)

Volume 9 Issue 1 January 2026

Review Article

Lutein in Vision and Eye Health

Dinal Vaghela[1]*, Debabrata Sarkar[2] and Ronak Chhaya[2]

[1]*QA Department, BioAni India Pvt. Ltd., India*

[2]*Research and Development Division, BioAni India Pvt. Ltd., India*

***Corresponding Author:** Dinal Vaghela, QA Department, BioAni India Pvt. Ltd., Lilapur, Ahmedabad, Gujarat, India.

Received: July 29, 2026

Published: September 03, 2026

Abstract

Lutein is a naturally occurring oxygenated carotenoid (xanthophyll) that cannot be synthesized by humans and must therefore be obtained through dietary sources or nutritional supplementation. Owing to its selective accumulation in the macula of the retina, lutein plays an important role in maintaining retinal integrity and visual function. Increasing evidence suggests that oxidative stress, chronic inflammation, mitochondrial dysfunction, and photo-oxidative damage contribute to the pathogenesis of several ocular disorders, including age-related macular degeneration (AMD), diabetic retinopathy (DR), cataract, and digital eye strain. Lutein exhibits potent antioxidant, anti-inflammatory, neuroprotective, anti-apoptotic, and blue light-filtering properties that protect retinal pigment epithelial cells and photoreceptors from oxidative injury. Experimental, epidemiological, and clinical studies have demonstrated that lutein supplementation increases macular pigment optical density (MPOD), improves visual performance, and may reduce the progression of age-related ocular diseases. Emerging evidence also indicates potential benefits in diabetic retinopathy, cataract prevention, and alleviation of digital eye strain through the reduction of oxidative stress, modulation of inflammatory pathways, and preservation of retinal function. This review summarizes the chemistry, physicochemical properties, dietary sources, absorption, bioavailability, metabolism, molecular mechanisms, clinical evidence, safety profile, and therapeutic applications of lutein in ocular health. Furthermore, current limitations and future research perspectives are discussed to provide a comprehensive overview of lutein as a promising nutraceutical for the prevention and management of vision-related disorders.

Keywords: Lutein; Eye Health; Xanthophyll; Carotenoids; Age-Related Macular Degeneration; Diabetic Retinopathy; Cataract; Digital Eye Strain; Macular Pigment Optical Density (MPOD); Antioxidant; Blue Light Filtration; Nutraceuticals

Abbreviations

AMD: age-Related Macular Degeneration; DR: Diabetic Retinopathy; MPOD: Macular Pigment Optical Density; ROS: Reactive Oxygen Species; RPE: Retinal Pigment Epithelial; SR-BI: Scavenger Receptor Class B Type I; CD36: Cluster Determinant 36; NPC1L1: Niemann–Pick C1-Like Protein 1; HDL: High-Density Lipoproteins; LDL: Low-Density Lipoproteins; SOD: Superoxide Dismutase; CAT: Catalase; GPX: Glutathione Peroxidase; NF-κB: Nuclear Factor Kappa B; COX-2: Cyclooxygenase-2; iNOS: Inducible Nitric Oxide Synthase; TNF-α: Tumor Necrosis Factor-Alpha; IL-1β: Interleukin-1 Beta; IL-6: Interleukin-6; VEGF: Vascular Endothelial Growth Factor; MDA: Malondialdehyde; DNA: Deoxyribonucleic Acid; DES: Digital Eye Strain; CVS: Computer Vision Syndrome; AREDS2: Age-Related Eye Disease Study 2; LAST: Lutein Antioxidant Supplementation Trial; CARMIS: Carotenoids and Antioxidants in

Age-Related Maculopathy Italian Study; CLEAR: Combination of Lutein Effects in the Aging Retina.

Introduction

Vision is one of the most essential sensory functions in humans, and maintaining retinal health is fundamental for preserving visual performance, independence, and quality of life throughout aging [1,3,4]. In recent decades, the global burden of ocular diseases has increased considerably owing to population aging, diabetes mellitus, unhealthy lifestyles, environmental pollution, and prolonged exposure to digital screens [1,3,6]. Age-related macular degeneration (AMD), diabetic retinopathy (DR), cataract, glaucoma, myopia, and digital eye strain have become major causes of visual impairment and blindness worldwide [1,3,6]. Although these disorders differ in their clinical manifestations, they share common pathological mechanisms, including oxidative stress, chronic inflammation, mitochondrial dysfunction, lipid peroxidation, and photo-oxidative damage, which collectively contribute to retinal degeneration and progressive vision loss [1,3,4]. Consequently, increasing attention has been directed toward nutritional interventions capable of protecting ocular tissues, preserving retinal function, and delaying the progression of vision-threatening diseases [1,3,4].

Lutein is a naturally occurring oxygenated carotenoid (xanthophyll) that cannot be synthesized by humans and must therefore be obtained through dietary sources [7,9-11]. Numerous studies have reported that increased lutein intake, either from food or supplementation, may contribute to ocular health by reducing the risk and progression of age-related macular degeneration (AMD) and cataract formation [8,12-16].

The protective effects of lutein are primarily attributed to its potent antioxidant, anti-inflammatory, neuroprotective, and blue light-filtering properties [1,3,4]. Owing to its highly conjugated molecular structure, lutein efficiently scavenges reactive oxygen species (ROS), quenches singlet oxygen, inhibits lipid peroxidation, and protects photoreceptor cells and retinal pigment epithelial (RPE) cells from oxidative injury [1,3,4]. Furthermore, lutein selectively absorbs high-energy blue light (approximately 400–500 nm), thereby minimizing photo-oxidative damage induced by sunlight and prolonged exposure to digital devices [3,4]. These multiple biological activities collectively provide the mechanistic basis for the protective effects of lutein against retinal degeneration and age-related ocular diseases [1,3,4].

Substantial experimental, epidemiological, and clinical evidence supports the beneficial role of lutein in maintaining ocular health [2,3]. Several clinical studies and systematic reviews have demonstrated that lutein supplementation improves macular pigment optical density (MPOD), enhances visual function [2,3,7-11].

More recently, the potential application of lutein has expanded beyond age-related ocular diseases to include protection against digital eye strain associated with prolonged electronic screen use [5,6]. A recent randomized, double-blind, placebo-controlled clinical trial demonstrated that daily supplementation with 10 mg lutein and 2 mg zeaxanthin for six months significantly improved tear production, tear film stability, photo stress recovery time, and several objective markers of ocular surface health in individuals using electronic screens for more than six hours per day [5]. These findings suggest that lutein may contribute not only to retinal protection but also to maintaining ocular comfort and visual performance in the modern digital era [5].

Despite substantial advances in lutein research, variations in supplementation dosage, treatment duration, bioavailability, study design, and patient characteristics have resulted in inconsistent findings across clinical investigations [1,3,6]. Therefore, a comprehensive synthesis of current scientific evidence is necessary to critically evaluate the chemistry, dietary sources, bioavailability, molecular mechanisms, pharmacological activities, clinical efficacy, safety, and therapeutic potential of lutein in maintaining eye health and preventing ocular diseases [1-3].

The present review comprehensively summarizes the available evidence regarding the biological characteristics, absorption, metabolism, mechanisms of action, clinical applications, safety profile, and therapeutic efficacy of lutein in the prevention and management of ocular disorders, with particular emphasis on age-related macular degeneration, diabetic retinopathy, cataract, myopia, digital eye strain, and other vision-related conditions [1,3]. Furthermore, this review highlights recent advances, current limitations, and future research perspectives to provide a comprehensive understanding of lutein as a promising nutraceutical for promoting long-term visual health [1,3].

Chemical structure and physicochemical properties of lutein

Lutein is a naturally occurring oxygenated carotenoid belonging to the xanthophyll family and is one of the predominant carotenoids present in the human retina [1,3,4]. Chemically, lutein has the molecular formula $C_{40}H_{56}O_2$ and a molecular weight of approximately 568.9 Da [1,3,4]. Unlike hydrocarbon carotenoids, lutein contains two hydroxyl (-OH) groups located at both ends of the molecule, which increase its polarity and distinguish it from non-oxygenated carotenoids such as β-carotene [1,3,4]. The molecule consists of a long chain of conjugated double bonds that is responsible for its characteristic yellow colour as well as its ability to absorb visible light and quench reactive oxygen species (ROS). These structural characteristics are considered fundamental to its antioxidant activity and its protective role in ocular tissues [1,3,4].



Figure 1: Illustrates the chemical structure of lutein ($C_{40}H_{56}O_2$), highlighting its conjugated polyene chain, β-ionone and ε-ionone rings, and terminal hydroxyl (–OH) groups. These structural features are responsible for its antioxidant activity, blue light-filtering ability, and protective effects on retinal tissues.

Lutein possesses an asymmetric molecular structure with one β-ionone ring and one ε-ionone ring connected by a polyene chain containing multiple conjugated double bonds [3,4]. The extended conjugated double-bond system enables efficient scavenging of singlet oxygen, neutralization of free radicals, and inhibition of lipid peroxidation [1,3,4]. These properties contribute significantly to the protection of retinal pigment epithelial (RPE) cells and photoreceptors from oxidative damage induced by aging, environmental stressors, and high-energy visible light [1,3,4]. The presence of terminal hydroxyl groups also facilitates its orientation within biological membranes, where lutein spans the phospholipid bilayer and stabilizes membrane integrity while protecting polyunsaturated fatty acids from oxidative degradation [1,4].

Lutein is a lipophilic compound that exhibits poor solubility in water but is readily soluble in organic solvents and dietary lipids [1,3,4]. Consequently, its intestinal absorption depends on the presence of dietary fat and bile acids, which promote micelle formation and facilitate uptake by intestinal epithelial cells [1,3]. Following absorption, lutein is incorporated into chylomicrons, transported through the lymphatic system, and subsequently distributed to various tissues via circulating lipoproteins [1,3]. The highest concentrations are found in the macula of the retina, where lutein accumulates together with zeaxanthin and meso-zeaxanthin to form the macular pigment [1,3,4]. This selective localization is essential for filtering high-energy blue light and reducing photo-oxidative stress within the retina [1,3,4].

The physicochemical characteristics of lutein also influence its stability [1,3,6]. The compound is sensitive to oxygen, heat, acidic conditions, and prolonged exposure to light, all of which may promote oxidation and isomerization, thereby reducing its biological activity [1,3,4]. Appropriate processing, storage, and formulation strategies are therefore important to preserve lutein stability and maximize its bioavailability in dietary supplements and functional foods [1,3,6]. Recent advances in formulation technologies, including lipid-based delivery systems and nano formulations, have been investigated to improve lutein stability, absorption, and therapeutic efficacy [3,6].

Overall, the unique chemical structure and physicochemical properties of lutein provide the molecular basis for its antioxidant, blue light-filtering, anti-inflammatory, and neuroprotective functions [3]. These characteristics explain its preferential accumulation in the macula and support its growing application as a nutraceutical for maintaining retinal health and preventing vision-related disorders [1,3].

Dietary sources of lutein

Lutein is a naturally occurring dietary xanthophyll that cannot be synthesized by humans and must therefore be obtained through food or nutritional supplementation [1,3,4]. It is widely distributed in green leafy vegetables, fruits, flowers, and several cereal crops, where it functions as a photosynthetic pigment and antioxidant [1,4]. Among naturally occurring carotenoids, lutein represents one of the richest dietary antioxidants and serves as the principal carotenoid accumulated in the human retina [1,3,4]. Regular consumption of lutein-rich foods has been associated with increased serum lutein concentrations, enhanced macular pigment optical density (MPOD), and improved visual performance, thereby contributing to the prevention of age-related ocular disorders [2-4].

Dark green leafy vegetables constitute the primary dietary source of lutein because chlorophyll masks their yellow pigmentation [1,4]. Vegetables such as spinach, kale, collard greens, parsley, broccoli, peas, lettuce, and green beans contain high concentrations of lutein and are considered the most important contributors to daily dietary intake [1,4]. Other vegetables, including corn, pumpkin, zucchini, and yellow peppers, also provide appreciable amounts of lutein [1,4]. In addition, several fruits, including kiwi, grapes, oranges, avocados, and certain berries, contribute moderate quantities of lutein to the human diet [1,4].

Egg yolk represents one of the most bioavailable dietary sources of lutein despite containing lower absolute concentrations than leafy vegetables [1,2,4]. The lipid-rich matrix of egg yolk enhances intestinal absorption of lutein, resulting in greater bioavailability than that obtained from many plant sources [2-4]. Consequently, regular consumption of eggs has been shown to increase serum lutein levels and macular pigment density without adversely affecting ocular health [2,3]. This observation highlights that both the quantity of lutein and the food matrix significantly influence its nutritional effectiveness [2-4].

The lutein content of foods varies considerably depending on plant variety, agricultural practices, climatic conditions, stage of maturity, post-harvest storage, and food processing methods [1,4]. Thermal processing, prolonged exposure to oxygen, and light may decrease lutein concentration through oxidative degradation and isomerization [1,4]. Conversely, mild cooking and the addition of dietary fats may improve the release of lutein from plant tissues and enhance its intestinal absorption [1,3]. Therefore, consuming lutein-rich vegetables together with healthy dietary fats such as vegetable oils, nuts, or avocados may improve lutein bioavailability [1,3].

Because habitual dietary intake of lutein is frequently lower than the amounts used in clinical studies, nutritional supplementation has gained increasing attention as an effective strategy for improving lutein status and supporting ocular health [1,3,6]. Most clinical trials evaluating the effects of lutein on age-related macular degeneration, diabetic retinopathy, cataract, and digital eye strain have administered daily doses ranging from 10 to 20 mg, either alone or in combination with zeaxanthin and other antioxidants [3,5,6]. These supplementation strategies have consistently demonstrated improvements in macular pigment optical density, visual acuity, contrast sensitivity, and several biomarkers of retinal function [2,3,5].

Overall, a balanced diet rich in green leafy vegetables, colourful fruits, and egg yolk remains the primary recommendation for achieving adequate lutein intake [1,4]. However, in individuals with insufficient dietary consumption or those at increased risk of ocular diseases, lutein supplementation may represent a practical nutritional approach to enhance retinal lutein levels and support long-term visual health [1,3,5,6].

Absorption, bioavailability and metabolism of lutein

Lutein is a lipophilic xanthophyll carotenoid whose biological efficacy largely depends on its absorption, bioavailability, tissue distribution, and metabolism [1,3,4]. Since humans are unable to synthesize lutein endogenously, adequate dietary intake and efficient intestinal absorption are essential for maintaining optimal circulating and retinal lutein concentrations [1,3,4]. However, the bioavailability of lutein is influenced by several dietary, physiological, and biochemical factors, resulting in considerable interindividual variation in its absorption and tissue accumulation [1-3].

Following ingestion, lutein is released from the food matrix during digestion and is incorporated into mixed micelles in the presence of bile salts, phospholipids, and dietary lipids [1,3,4]. Because lutein is fat-soluble, the presence of dietary fat significantly enhances its solubilization and intestinal uptake [1,3,4].

Mixed micelles facilitate the transport of lutein across the unstirred water layer to the brush border membrane of enterocytes, where absorption occurs primarily through passive diffusion as well as transporter-mediated mechanisms involving scavenger receptor class B type I (SR-BI), cluster determinant 36 (CD36), and Niemann–Pick C1-like protein 1 (NPC1L1) [3,4].

After intestinal absorption, lutein is incorporated into chylomicrons and transported through the lymphatic system before entering the systemic circulation [1,3,4]. Chylomicron remnants deliver lutein to the liver, where it is redistributed into circulating lipoproteins, predominantly high-density lipoproteins (HDL) and low-density lipoproteins (LDL) [1,3]. These lipoproteins serve as the principal carriers responsible for transporting lutein to peripheral tissues, including the retina, brain, skin, and other organs [1,3,4]. Among these tissues, the macular region of the retina selectively accumulates lutein together with zeaxanthin and meso-zeaxanthin to form the macular pigment, which plays a critical role in protecting retinal cells against oxidative stress and blue light-induced damage [1,3,4].

Several factors influence the bioavailability of lutein. Dietary composition is one of the most important determinants, as co-consumption of dietary fats markedly improves lutein absorption by promoting micelle formation [4]. Conversely, excessive dietary Fiber and certain food processing conditions may reduce bioavailability by limiting carotenoid release from the food matrix [1,3]. Food matrix characteristics also influence absorption; for example, lutein from egg yolk exhibits higher bioavailability than lutein from many vegetable sources because of the lipid-rich environment that facilitates intestinal uptake [2-4]. In addition, age, gastrointestinal health, genetic polymorphisms affecting carotenoid transport proteins, nutritional status, and interactions with other dietary carotenoids may further contribute to individual differences in lutein bioavailability [1,3,4].

Following tissue uptake, lutein preferentially accumulates within the macula, where it contributes to macular pigment optical density (MPOD) [1,2-4]. Its unique localization allows selective absorption of high-energy blue light while simultaneously neutralizing reactive oxygen species generated during photochemical reactions [1,3,4]. This dual protective function preserves the structural integrity of photoreceptors and retinal pigment epithelial (RPE) cells, thereby maintaining normal retinal function and reducing the risk of retinal degeneration [1,3,4]. Although lutein undergoes limited metabolic transformation compared with several other carotenoids, oxidative metabolites have been identified in ocular tissues and may also contribute to its biological activity [1,3,4]. Nevertheless, the precise metabolic pathways and physiological significance of these metabolites require further investigation [1,3,6].

Because natural lutein exhibits relatively low aqueous solubility and variable oral bioavailability, several formulation strategies have been developed to improve its absorption and therapeutic efficacy [1,3,6]. Lipid-based formulations, emulsions, microencapsulation, nanotechnology-based delivery systems, and phospholipid complexes have demonstrated improved stability, enhanced intestinal absorption, and increased systemic availability compared with conventional preparations [1,3,6]. These advanced delivery systems may enhance retinal lutein accumulation and optimize its protective effects against age-related ocular diseases [3,6].

Overall, the absorption, bioavailability, and metabolism of lutein are critical determinants of its biological effectiveness [1,3,4]. Efficient intestinal absorption, lipoprotein-mediated transport, selective retinal accumulation, and favourable formulation strategies collectively influence lutein availability in ocular tissues and ultimately determine its potential in preventing oxidative retinal damage and preserving long-term visual function [1,3,4,6].

Mechanisms of action of lutein

The beneficial effects of lutein on ocular health are mediated through multiple complementary biological mechanisms that collectively protect retinal tissues against oxidative stress, inflammation, and photo-induced cellular damage [1,3,4]. Because the retina has one of the highest oxygen consumption rates in the human body and is continuously exposed to visible light, it is highly susceptible to oxidative injury [1,3,4]. Lutein exerts protective effects by functioning as a potent antioxidant, filtering high-energy blue light, suppressing inflammatory responses, preserving mitochondrial function, inhibiting apoptosis, and maintaining retinal structural integrity [1,3,4,6]. These diverse mechanisms contribute to its therapeutic potential in age-related macular degeneration (AMD), diabetic retinopathy (DR), cataract, and other retinal disorders [1,3,6].

Antioxidant activity

Oxidative stress is recognized as one of the principal pathogenic mechanisms underlying retinal degeneration and age-related ocular diseases [1,3,4]. Excessive production of reactive oxygen species (ROS) results in oxidative damage to lipids, proteins, DNA, and cellular organelles, ultimately impairing the function of photoreceptors and retinal pigment epithelial (RPE) cells [1,3,4]. Lutein possesses a highly conjugated polyene chain that enables efficient scavenging of free radicals and quenching of singlet oxygen, thereby limiting oxidative damage within retinal tissues. By reducing lipid peroxidation and maintaining cellular redox homeostasis, lutein preserves membrane integrity and protects retinal cells against oxidative injury [1,3,4].

Experimental studies have demonstrated that lutein enhances endogenous antioxidant defense systems by increasing the activity of antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), while simultaneously reducing oxidative biomarkers such as malondialdehyde (MDA) [1,3,6]. These antioxidant effects play a critical role in preserving retinal function and slowing the progression of degenerative ocular diseases [1,3,6].

Anti-inflammatory activity

Chronic inflammation contributes significantly to the development and progression of retinal diseases [1,3,4]. Persistent oxidative stress activates inflammatory signalling pathways, resulting in increased production of pro-inflammatory cytokines and mediators that promote retinal injury [1,3,4]. Lutein has been shown to suppress inflammatory responses by inhibiting activation of nuclear factor-kappa B (NF-κB), thereby reducing the expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). Consequently, lutein reduces inflammatory damage within retinal tissues and contributes to the preservation of retinal structure and function [1,3,4,6].

Blue light-filtering property

One of the unique physiological characteristics of lutein is its selective accumulation within the macular region of the retina, where it forms the macular pigment together with zeaxanthin and meso-zeaxanthin [1,3,4]. Macular pigment selectively absorbs high-energy blue light within the wavelength range of approximately 400–500 nm, thereby reducing the amount of potentially harmful light reaching the photoreceptors and retinal pigment epithelium [1,3,4]. This optical filtering function decreases photo-oxidative stress, limits the formation of reactive oxygen species, and protects retinal cells from cumulative light-induced damage associated with aging and prolonged digital screen exposure [1,3,4,5].

Neuroprotective activity

In addition to its antioxidant and anti-inflammatory effects, lutein exhibits significant neuroprotective properties within retinal tissues [1,3,4]. Experimental studies have demonstrated that lutein preserves retinal ganglion cells and photoreceptors by maintaining mitochondrial function, reducing oxidative injury, and improving cellular energy metabolism [1,3,4]. Furthermore, lutein supports the structural integrity of retinal neurons and retinal pigment epithelial cells, thereby contributing to maintenance of normal visual function and slowing retinal degeneration [1,3,4]. These neuroprotective effects are considered particularly important in chronic retinal disorders characterized by progressive neuronal loss [1,3,4,6].

Anti-apoptotic activity

Apoptosis of retinal pigment epithelial cells and photoreceptors is a major pathological feature of several ocular diseases, including AMD and diabetic retinopathy [1,3,4]. Oxidative stress and chronic inflammation activate intrinsic apoptotic pathways that ultimately result in retinal cell death [1,3,4]. Lutein has been reported to inhibit apoptosis by reducing oxidative stress, preserving mitochondrial membrane integrity, and regulating apoptosis-related proteins [1,3,4]. Experimental evidence suggests that lutein decreases the expression of pro-apoptotic mediators while promoting cell survival pathways, thereby protecting retinal cells from degeneration and maintaining retinal architecture [1,3,4].

Anti-angiogenic activity

Abnormal angiogenesis contributes to the development of advanced retinal diseases, particularly neovascular age-related macular degeneration and diabetic retinopathy [1,3,4]. Increased oxidative stress stimulates vascular endothelial growth factor (VEGF) expression, resulting in pathological neovascularization and increased vascular permeability [1,3,4]. Several experimental studies have demonstrated that lutein suppresses VEGF expression and inhibits angiogenic signalling pathways, thereby reducing retinal vascular leakage and abnormal blood vessel formation [1,3,4,6]. These anti-angiogenic properties further support the therapeutic potential of lutein in preventing the progression of retinal vascular disorders [1,3,4,6].

LUTEIN

↓

Antioxidant • Anti-inflammatory

Blue-light filtration

Neuroprotection

↓

AMD | DR | Cataract | Digital Eye Strain

↓

Improved retinal health

Better visual function

Reduced disease progression

Figure 2: Illustrates the major mechanisms of action of lutein, including antioxidant, anti-inflammatory, blue light-filtering, and neuroprotective activities, which contribute to retinal protection. These mechanisms support the prevention and management of age-related macular degeneration (AMD), diabetic retinopathy (DR), cataract, and digital eye strain, leading to improved visual function and retinal health.

Role of lutein in age-related macular degeneration (AMD)

Age-related macular degeneration (AMD) is a progressive degenerative disorder affecting the macula, the central region of the retina responsible for high-acuity vision [1,3,4]. It is one of the leading causes of irreversible visual impairment and blindness among older adults worldwide [1,3,4]. The prevalence of AMD continues to increase because of population aging and the growing burden of chronic diseases [1,3,4]. The pathogenesis of AMD is multifactorial and involves oxidative stress, chronic inflammation, mitochondrial dysfunction, lipid peroxidation, complement activation, and retinal pigment epithelial (RPE) cell degeneration [1,3,4]. These pathological processes ultimately result in photoreceptor loss and progressive deterioration of central vision [1,3,4].

Lutein has received considerable attention as a nutritional intervention for AMD because it is one of the major carotenoids selectively concentrated within the macular pigment [1,3,4]. Together with zeaxanthin and meso-zeaxanthin, lutein forms the macular pigment, which serves as the first line of defence against photo-oxidative retinal damage [1,3,4]. By selectively absorbing high-energy blue light, lutein reduces light-induced oxidative stress and limits the generation of reactive oxygen species (ROS), thereby protecting photoreceptors and retinal pigment epithelial cells from cumulative damage [1,3,4]. In addition to its optical filtering function, lutein exhibits potent antioxidant and anti-inflammatory activities that further contribute to retinal protection [1,3,4,6].

Oxidative stress plays a central role in the initiation and progression of AMD because retinal tissues have high metabolic activity and are continuously exposed to oxygen and visible light [1,3,4]. Excessive ROS production promotes lipid peroxidation, DNA damage, protein oxidation, and mitochondrial dysfunction, ultimately leading to apoptosis of retinal pigment epithelial cells [1,3,4]. Lutein effectively scavenges reactive oxygen species, quenches singlet oxygen, and enhances endogenous antioxidant defence mechanisms, thereby reducing oxidative damage within the retina [1,3,4]. Experimental studies have also demonstrated that lutein suppresses inflammatory mediators and modulates complement activation, both of which are important contributors to AMD progression [1,3,4,6].

Several epidemiological investigations have reported an inverse association between dietary lutein intake and the risk of AMD [1,4,6]. Individuals with higher dietary consumption of lutein-rich foods generally exhibit greater macular pigment optical density (MPOD) and a lower incidence of advanced retinal degeneration [1,4,6]. These findings suggest that long-term consumption of lutein-containing foods may contribute to maintenance of retinal health and preservation of visual function during aging [1,4,6].

Clinical evidence further supports the beneficial role of lutein in AMD management [1,3,4]. The Age-Related Eye Disease Study 2 (AREDS2) demonstrated that replacing β-carotene with lutein and zeaxanthin in the original AREDS formulation improved retinal carotenoid status and reduced the risk of progression to advanced AMD, particularly among individuals with low baseline dietary carotenoid intake [3,4]. Other randomized clinical trials, including the Lutein Antioxidant Supplementation Trial (LAST), the Carotenoids and Antioxidants in Age-Related Maculopathy Italian Study (CARMIS), and the Combination of Lutein Effects in the Aging Retina (CLEAR) study, have consistently reported improvements in macular pigment optical density, visual acuity, contrast sensitivity, glare recovery, and overall visual performance following lutein supplementation [7-11].

The protective effects of lutein in AMD are not limited to structural preservation of the retina but also include functional improvements [1,3,4]. Increased macular pigment density enhances visual performance by improving contrast sensitivity, reducing glare disability, shortening photo stress recovery time, and improving visual comfort under different lighting conditions [7-11]. These functional benefits are particularly important for older adults because they contribute to improved daily activities, reading ability, driving performance, and overall quality of life [1,3,4].

Despite the substantial evidence supporting lutein supplementation, treatment outcomes may vary depending on dosage, duration of supplementation, baseline nutritional status, disease severity, genetic factors, and individual differences in carotenoid absorption and metabolism [1,3,4]. Most clinical studies have reported beneficial effects using daily lutein doses ranging from 10 to 20 mg, particularly when administered in combination with zeaxanthin and other antioxidant nutrients [3,4,7,8,10,11]. Nevertheless, further long-term randomized controlled trials are required to establish optimal supplementation strategies and to determine the long-term clinical efficacy of lutein across different stages of AMD [1,3,4,6].

Overall, the available experimental, epidemiological, and clinical evidence strongly supports the beneficial role of lutein in the prevention and management of age-related macular degeneration [1,3,4,6]. Through its antioxidant, anti-inflammatory, blue light-filtering, and neuroprotective properties, lutein contributes to preservation of retinal structure and function, increases macular pigment optical density, improves visual performance, and may reduce the progression of advanced AMD [1,3,4,6-11]. These findings support lutein as an important nutritional strategy for maintaining long-term macular health and reducing age-related vision loss [1,3,4,6].

Role of lutein in diabetic retinopathy (DR)

Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes mellitus and remains a leading cause of vision impairment and blindness among the working-age population worldwide [1,3,4]. Chronic hyperglycaemia induces a series of metabolic abnormalities that lead to retinal vascular dysfunction, increased oxidative stress, chronic inflammation, neuronal degeneration, and disruption of the blood-retinal barrier [1,3,4]. Progressive retinal ischemia, capillary leakage, and pathological neovascularization ultimately result in visual deterioration if left untreated [1,3,4]. Growing evidence suggests that oxidative stress and inflammation play central roles in the pathogenesis of DR, making antioxidant-based nutritional interventions an attractive therapeutic strategy [1,3,4,6].

Lutein has emerged as a promising nutraceutical for diabetic retinopathy because of its potent antioxidant, anti-inflammatory, and neuroprotective properties [1,3,4,6]. As one of the principal carotenoids selectively accumulated in the retina, lutein protects retinal tissues against oxidative injury by scavenging reactive oxygen species (ROS), quenching singlet oxygen, and reducing lipid peroxidation [1,3,4]. These antioxidant activities help preserve retinal pigment epithelial (RPE) cells, photoreceptors, and retinal neurons from hyperglycaemia-induced oxidative damage, thereby slowing retinal degeneration associated with diabetes [1,3,4].

Persistent hyperglycaemia stimulates the production of inflammatory cytokines and activates multiple signalling pathways that contribute to retinal injury [1,3,4]. Experimental studies have demonstrated that lutein suppresses inflammatory mediators by inhibiting nuclear factor-kappa B (NF-κB) activation and reducing the expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), tumour necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) [1,3,4]. By attenuating these inflammatory responses, lutein reduces retinal inflammation and helps preserve the structural integrity of retinal tissues [1,3,4,6].

Neurodegeneration is increasingly recognized as an early event in diabetic retinopathy that may occur before the appearance of clinically detectable vascular abnormalities [1,3,4]. Experimental studies have shown that lutein protects retinal ganglion cells and photoreceptors by preserving mitochondrial function, reducing apoptosis, and maintaining normal retinal architecture [1,3,4]. These neuroprotective effects contribute to improved retinal function and may delay disease progression in diabetic individuals [1,3,4,6].

Abnormal angiogenesis mediated by vascular endothelial growth factor (VEGF) is another hallmark of advanced diabetic retinopathy [1,3,4]. Increased oxidative stress promotes VEGF overexpression, resulting in pathological neovascularization and increased vascular permeability [1,3,4]. Several experimental investigations have reported that lutein suppresses VEGF expression and reduces retinal vascular leakage, thereby limiting pathological angiogenesis and preserving retinal vascular integrity [1,3,4,6]. These findings suggest that lutein may provide additional therapeutic benefits during the later stages of diabetic retinopathy [1,3,4,6].

Animal studies have consistently demonstrated that lutein supplementation reduces retinal oxidative stress, decreases inflammatory responses, preserves retinal morphology, and improves retinal electrophysiological function in diabetic models [1,3,4]. Clinical evidence, although relatively limited compared with AMD, has also reported improvements in visual acuity, retinal thickness, and retinal function following lutein supplementation in patients with non-proliferative diabetic retinopathy [1,3,4]. However, variations in study design, dosage, treatment duration, and patient characteristics have resulted in inconsistent findings across clinical investigations [1,3,4,6]. Therefore, additional well-designed randomized controlled trials are required to establish the long-term efficacy of lutein supplementation in diabetic retinopathy [1,3,4,6].

The beneficial effects of lutein in diabetic retinopathy are likely mediated through multiple complementary mechanisms, including reduction of oxidative stress, suppression of chronic inflammation, inhibition of apoptosis, preservation of mitochondrial function, modulation of VEGF-mediated angiogenesis, and maintenance of retinal neuronal integrity [1,3,4,6]. These multifaceted biological actions support the potential use of lutein as an adjunctive nutritional therapy for preventing or delaying the progression of diabetic retinal complications [1,3,4,6].

Overall, current experimental and clinical evidence suggests that lutein may contribute to the prevention and management of diabetic retinopathy by protecting retinal tissues against hyperglycaemia-induced oxidative stress and inflammation while preserving retinal structure and visual function [1,3,4,6]. Although additional large-scale clinical studies are needed to confirm its therapeutic effectiveness, lutein represents a promising nutritional intervention for supporting retinal health in individuals with diabetes [1,3,4,6].

Role of lutein in cataract

Cataract is a progressive ocular disorder characterized by clouding of the crystalline lens, resulting in decreased visual acuity and impaired quality of life [1,3,4]. It remains the leading cause of blindness worldwide despite the availability of surgical treatment [1,3,4]. Age-related cataract develops through complex biochemical and molecular mechanisms involving oxidative stress, protein aggregation, lipid peroxidation, chronic inflammation, and age-associated degeneration of lens epithelial cells [1,3,4]. Continuous exposure of the lens to ultraviolet radiation, reactive oxygen species (ROS), environmental pollutants, smoking, diabetes mellitus, and aging further accelerates lens opacity and cataract formation [1,3,4]. Therefore, nutritional antioxidants have attracted considerable attention as potential preventive strategies against cataract development [1,3,4,6].

Lutein has been extensively investigated for its protective effects against cataract because of its potent antioxidant properties and its ability to neutralize oxidative stress within ocular tissues [1,3,4]. As an oxygenated carotenoid (xanthophyll), lutein efficiently scavenges reactive oxygen species, quenches singlet oxygen, and inhibits lipid peroxidation, thereby protecting lens proteins and membrane lipids from oxidative damage [1,3,4]. Preservation of lens transparency largely depends on maintaining the structural integrity of crystallin proteins, and lutein plays an important role in preventing oxidative modification and aggregation of these proteins, which are key events in cataract genesis [1,3,4].

The antioxidant effects of lutein are further supported by its ability to enhance endogenous antioxidant defence mechanisms [1,3,6]. Experimental studies have demonstrated that lutein increases the activity of antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), while reducing oxidative biomarkers such as malondialdehyde (MDA) [1,3,6]. These actions help maintain redox balance within the lens and reduce oxidative injury associated with aging and metabolic disorders [1,3,6].

In addition to its antioxidant activity, lutein exhibits anti-inflammatory properties that may contribute to cataract prevention [1,3,4]. Chronic inflammation enhances oxidative damage within lens epithelial cells through activation of inflammatory mediators and signalling pathways [1,3,4]. Lutein suppresses inflammatory responses by inhibiting nuclear factor-kappa B (NF-κB) activation and reducing the production of pro-inflammatory cytokines, thereby minimizing inflammation-induced cellular injury and preserving lens function [1,3,4].

Epidemiological studies have consistently reported that individuals with higher dietary intake or higher serum concentrations of lutein exhibit a lower risk of age-related cataract [12-16]. Regular consumption of lutein-rich foods, including green leafy vegetables and egg yolk, has been associated with reduced incidence of nuclear and cortical cataracts [12-16]. These findings suggest that long-term dietary intake of lutein may contribute to maintenance of lens transparency and delay cataract progression [12-16].

Clinical investigations have also evaluated the role of lutein supplementation in cataract prevention and visual function [1,3,4]. Although the magnitude of benefit varies among studies, several clinical trials have demonstrated improvements in visual performance and reduced progression of lens opacity following lutein supplementation, particularly in individuals with low baseline dietary carotenoid intake [1,3,4,12-14]. However, differences in supplementation dose, treatment duration, patient characteristics, and study design have produced inconsistent clinical outcomes [1,3,4,6]. Consequently, further large-scale randomized controlled trials are required to establish the optimal dosage and long-term therapeutic efficacy of lutein in cataract prevention [1,3,4,6].

The protective effects of lutein against cataract are mediated through multiple complementary mechanisms, including scavenging of reactive oxygen species, inhibition of lipid peroxidation, enhancement of endogenous antioxidant defences, suppression of inflammatory signalling pathways, and preservation of lens protein stability [1,3,4,6]. Collectively, these biological actions help maintain lens transparency, reduce oxidative injury, and delay age-related degenerative changes within the crystalline lens [1,3,4,6].

Overall, current experimental, epidemiological, and clinical evidence supports the beneficial role of lutein in maintaining lens health and reducing the risk of cataract formation [1,3,4,6,12-16]. Although cataract surgery remains the definitive treatment for advanced disease, adequate dietary intake and appropriate supplementation of lutein may serve as an effective nutritional strategy for delaying cataract development and preserving visual function during aging [1,3,4,6].

Role of lutein in digital eye strain (Computer Vision Syndrome)

Digital eye strain (DES), also referred to as computer vision syndrome (CVS), has emerged as a significant public health concern due to the widespread use of digital devices, including computers, smartphones, tablets, and televisions [5,6]. Prolonged exposure to digital screens is associated with various ocular symptoms, including eye fatigue, blurred vision, dry eyes, burning sensation, headache, photophobia, reduced contrast sensitivity, and delayed visual recovery [5,6]. The increasing prevalence of digital screen use in occupational, educational, and recreational settings has considerably increased the incidence of DES across all age groups [5,6]. Although the exact pathophysiology of digital eye strain is multifactorial, prolonged exposure to high-energy blue light, reduced blinking frequency, tear film instability, oxidative stress, and accommodative dysfunction are considered major contributing factors [5,6].

Lutein has gained increasing attention as a nutritional intervention for digital eye strain because of its unique ability to selectively accumulate within the macular pigment and absorb high-energy blue light before it reaches the photoreceptors [1,3,5]. By filtering blue light in the wavelength range of approximately 400–500 nm, lutein reduces photo-oxidative stress and minimizes the generation of reactive oxygen species within retinal tissues [1,3,5]. In addition to its optical filtering properties, lutein exhibits potent antioxidant and anti-inflammatory activities that further protect retinal cells from oxidative damage induced by prolonged exposure to electronic screens [1,3,5].

Experimental evidence suggests that prolonged blue-light exposure increases oxidative stress, damages retinal pigment epithelial (RPE) cells, and accelerates retinal aging [1,3,5]. Lutein protects retinal tissues by scavenging reactive oxygen species, inhibiting lipid peroxidation, preserving mitochondrial function, and reducing inflammatory responses [1,3,5,6]. These biological activities contribute to improved retinal resilience and maintenance of normal visual function during extended periods of digital device use [1,3,5,6].

Clinical evidence supporting the beneficial effects of lutein in digital eye strain has increased in recent years [5]. A randomized, double-blind, placebo-controlled clinical trial demonstrated that daily supplementation with 10 mg lutein and 2 mg zeaxanthin for six months significantly improved multiple objective indicators of ocular surface health in individuals who used electronic screens for more than six hours per day [5]. Supplementation resulted in significant improvements in tear secretion, tear film stability, photo stress recovery time, and overall visual comfort, indicating that lutein supplementation may effectively alleviate symptoms associated with prolonged screen exposure [5].

In addition to improvements in ocular surface parameters, lutein supplementation has been associated with enhanced macular pigment optical density (MPOD), improved contrast sensitivity, reduced glare sensitivity, and faster recovery following intense light exposure [1,4,5]. Increased macular pigment acts as a natural optical filter that improves visual performance under bright lighting conditions while reducing retinal stress caused by continuous blue-light exposure [1,4,5]. These functional improvements may enhance occupational productivity and reduce visual discomfort among individuals with extensive daily screen use [1,4,5].

Although current evidence demonstrates promising benefits of lutein supplementation for digital eye strain, further large-scale clinical trials involving diverse populations and longer intervention periods are required to establish optimal dosage, treatment duration, and long-term clinical effectiveness [5,6]. Future studies should also investigate the combined effects of lutein with other macular carotenoids and antioxidants in protecting against digital screen-induced retinal damage [5,6].

Overall, available experimental and clinical evidence suggests that lutein represents a promising nutritional strategy for reducing digital eye strain through multiple complementary mechanisms, including blue-light filtration, antioxidant protection, anti-inflammatory activity, and improvement of ocular surface function [1,3,5,6]. Regular dietary intake or appropriate supplementation of lutein may therefore contribute to maintaining visual comfort, retinal health, and optimal visual performance in the modern digital era [1,3,5,6].

Safety profile of lutein

Lutein is generally regarded as a safe and well-tolerated dietary carotenoid, with numerous experimental and clinical studies demonstrating an excellent safety profile following both dietary consumption and nutritional supplementation [1,3,4,6]. Because lutein is a naturally occurring constituent of commonly consumed fruits, vegetables, and egg yolk, regular dietary intake has not been associated with significant adverse health effects [1,3,4]. Clinical investigations evaluating lutein supplementation for ocular diseases have consistently reported good tolerability, with very few treatment-related adverse events [1,3,4,6].

Most randomized clinical trials investigating lutein supplementation have administered daily doses ranging from 10 to 20 mg, either alone or in combination with zeaxanthin and other antioxidant nutrients [1,4,6]. These doses have been shown to significantly increase serum lutein concentrations and macular pigment optical density (MPOD) without producing clinically significant toxicity [1,4,6]. Mild gastrointestinal discomfort has occasionally been reported; however, these symptoms are generally transient and do not require discontinuation of supplementation [1,4,6].

Long-term supplementation studies, including the Age-Related Eye Disease Study 2 (AREDS2), have further confirmed the safety of lutein in older adults at risk of age-related macular degeneration [1,4]. Importantly, replacement of β-carotene with lutein and zeaxanthin in the AREDS2 formulation reduced concerns regarding β-carotene-associated lung cancer risk in smokers while maintaining beneficial effects on ocular health [1,4]. This finding supports the use of lutein as a safer alternative carotenoid for long-term nutritional supplementation [1,4].

The safety of lutein is also supported by its physiological distribution within human tissues [1,3,6]. Following absorption, lutein is selectively accumulated in the retina, brain, skin, and other organs without evidence of harmful tissue deposition [1,3,6]. Although excessive dietary intake may occasionally result in carotenoderma, characterized by reversible yellow discoloration of the skin, this condition is considered harmless and resolves following reduction of carotenoid intake [1,3,6]. No evidence suggests that lutein supplementation causes retinal toxicity or visual impairment when consumed within recommended doses [1,3,6].

Despite its favourable safety profile, further long-term investigations are warranted to evaluate the effects of prolonged high-dose supplementation in different populations, including patients with chronic metabolic disorders and elderly individuals [1,6]. Additional studies are also required to determine potential interactions between lutein and other dietary carotenoids or pharmacological agents [1,6].

Overall, current scientific evidence indicates that lutein is a safe, well-tolerated, and effective nutritional supplement for supporting ocular health [1,3,4,6]. Its excellent safety profile, combined with demonstrated antioxidant, anti-inflammatory, and neuroprotective activities, supports its long-term use as a nutraceutical for the prevention and management of vision-related disorders [1,3,4,6].

Conclusion

Lutein is a naturally occurring dietary xanthophyll that plays an essential role in maintaining retinal health and preserving visual function. Because humans cannot synthesize lutein, adequate dietary intake or nutritional supplementation is necessary to achieve sufficient tissue concentrations. Its selective accumulation within the macular pigment, combined with its potent antioxidant, anti-inflammatory, blue light-filtering, neuroprotective, anti-apoptotic, and anti-angiogenic properties, provides a strong biological basis for its protective effects against retinal degeneration and age-related ocular diseases.

Accumulating experimental, epidemiological, and clinical evidence demonstrates that lutein contributes to the maintenance of ocular health by increasing macular pigment optical density, reducing oxidative stress, preserving retinal pigment epithelial cells, improving visual performance, and protecting against photo-oxidative damage. Clinical studies have consistently reported beneficial effects of lutein supplementation in age-related macular degeneration, while emerging evidence also supports its potential therapeutic role in diabetic retinopathy, cataract, and digital eye strain. Although additional large-scale randomized controlled trials are required to establish standardized treatment recommendations, the current evidence strongly supports lutein as an effective nutritional strategy for promoting long-term visual health.

Future research focusing on improved bioavailability, novel delivery systems, personalized nutritional approaches, and long-term clinical evaluation will further enhance our understanding of lutein's therapeutic potential. Based on the currently available scientific evidence, lutein represents a promising, safe, and well-tolerated nutraceutical with significant potential for the prevention and management of vision-related disorders. Continued research will further clarify its role in evidence-based ophthalmic nutrition and contribute to the development of effective nutritional strategies for preserving vision throughout life.

Bibliography

1. Buscemi S., *et al*. "The Effect of Lutein on Eye and Extra-Eye Health". *Nutrients* 10.9 (2018): 1321.
2. Wilson LM., *et al*. "The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis". *Advances in Nutrition* 12.6 (2021): 2244-2254.
3. Li L H., *et al*. "Lutein Supplementation for Eye Diseases". *Nutrients* 12.6 (2020): 1721.
4. Mares J. "Lutein and Zeaxanthin Isomers in Eye Health and Disease". *Annual Review of Nutrition* 36 (2016): 571-602.
5. Lopresti AL and Smith S J. "The Effects of Lutein/Zeaxanthin (Lute-gen®) on Eye Health, Eye Strain, Sleep Quality, and Attention in High Electronic Screen Users". *Frontiers in Nutrition* 12 (2025): 1522302.
6. Khajindar B., *et al*. "Exploring the Role of Lutein in Eye Health". *International Journal of Pharmacy and Chemistry* 11.4 (2025): 87-93.
7. Richer S., *et al*. "Double-Masked, Placebo-Controlled, Randomized Trial of Lutein and Antioxidant Supplementation in AMD". *Optometry* 75.4 (2004): 216-230.
8. Parisi V., *et al*. "Carotenoids and Antioxidants in Age-Related Maculopathy Italian Study". *Ophthalmology* 115.2 (2008): 324-333.
9. Weigert G., *et al*. "Effects of Lutein Supplementation on MPOD and Visual Acuity in AMD". *Investigative Ophthalmology and Visual Science* 52.11 (2011): 8174-8178.
10. Beatty S., *et al*. "Secondary Outcomes in a Clinical Trial of Carotenoids with Coantioxidants versus Placebo in Early AMD". *Ophthalmology* 120.3 (2013): 600-606.
11. Murray I J., *et al*. "The CLEAR Study". *Investigative Ophthalmology and Visual Science* 54.3 (2013): 1781-1788.
12. Christen WG., *et al*. "Dietary Carotenoids, Vitamins C and E, and Risk of Cataract in Women". *Archives of Ophthalmology* 126.1 (2008): 102-109.
13. Vu HT., *et al*. "Lutein and Zeaxanthin and the Risk of Cataract". *Investigative Ophthalmology and Visual Science* 47.9 (2006): 3783-3786.

14. Moeller S. M., *et al*. "CAREDS Study". *Archives of Ophthalmology* 126.3 (2008): 354-364.

15. Brown L., *et al*. "Carotenoid Intake and Cataract Extraction in Men". *The American Journal of Clinical Nutrition* 70.4 (1999): 517-524.

16. Chasan-Taber L., *et al*. "Carotenoid and Vitamin A Intake and Cataract Extraction in Women". *The American Journal of Clinical Nutrition* 70.4 (1999): 509-516.